A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease
Status:
Completed
Trial end date:
2017-11-22
Target enrollment:
Participant gender:
Summary
This is a Phase I study to investigate the safety and tolerability of AZD4831 in healthy male
participants, conducted at a single center. The results from this study will form the basis
for decisions on future studies. Another purpose of this dose escalation study is to find out
the right dose of the experimental drug to be given to study participants in future studies.
Even though there were no harmful effects seen in the animals tested, investigator does not
know what side effects the experimental drug might cause in humans. However, site personnel
managing the study participants will be blinded to the extent possible and as long as
possible to minimize any impact on data collection. Study participants will be blinded to
treatment allocation.
The study will be conducted in healthy participants to avoid interference from disease
processes or other drugs.
The participants will stay at the study center during the whole dosing period and until 48
hours post final dose.